Notably, this present study starkly contrasts with our earlier findings for reduced potency of LEV (and brivaracetam) in 6-Hz corneal-kindled mice in APP overexpressing AD models, revealing potential heterogeneity in ASM activity profiles in the setting of AD-related genotypes or intrinsic differences in the evoked seizure paradigms (12, 74). This evidence concerns the gene APP and Alzheimer disease.